CN116964084A - 双特异性抗体 - Google Patents
双特异性抗体 Download PDFInfo
- Publication number
- CN116964084A CN116964084A CN202280012964.0A CN202280012964A CN116964084A CN 116964084 A CN116964084 A CN 116964084A CN 202280012964 A CN202280012964 A CN 202280012964A CN 116964084 A CN116964084 A CN 116964084A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- terminus
- cancer
- domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410201902.5A CN118063620A (zh) | 2021-02-07 | 2022-01-27 | 双特异性抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021101789325 | 2021-02-07 | ||
| CN202110178932 | 2021-02-07 | ||
| CN202110937430 | 2021-08-16 | ||
| CN2021109374306 | 2021-08-16 | ||
| PCT/CN2022/074133 WO2022166728A1 (zh) | 2021-02-07 | 2022-01-27 | 双特异性抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410201902.5A Division CN118063620A (zh) | 2021-02-07 | 2022-01-27 | 双特异性抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116964084A true CN116964084A (zh) | 2023-10-27 |
Family
ID=82740913
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280012964.0A Pending CN116964084A (zh) | 2021-02-07 | 2022-01-27 | 双特异性抗体 |
| CN202410201902.5A Pending CN118063620A (zh) | 2021-02-07 | 2022-01-27 | 双特异性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410201902.5A Pending CN118063620A (zh) | 2021-02-07 | 2022-01-27 | 双特异性抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240092899A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4303231A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507693A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230141817A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116964084A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022215712A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023015217A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3210307A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304800A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023008966A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202233694A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022166728A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114885609A (zh) * | 2018-12-24 | 2022-08-09 | 赛诺菲 | 基于假Fab的多特异性结合蛋白 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202321312A (zh) * | 2021-09-08 | 2023-06-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 包含基於mhc或mhc樣蛋白的異源二聚體的二價雙特異性嵌合抗體 |
| CN118076644A (zh) * | 2021-09-30 | 2024-05-24 | 正大天晴药业集团股份有限公司 | 针对免疫检查点的双特异性抗体 |
| US20260209385A1 (en) * | 2022-12-08 | 2026-07-23 | Analytical Biosciences Shanghai Limited | Bispecific/multi-specific antibodies and uses thereof |
| WO2025213057A1 (en) * | 2024-04-04 | 2025-10-09 | Fletcher Biosciences, Inc. | Engineered major histocompatibility complex molecules and uses thereof |
| WO2026061376A1 (zh) * | 2024-09-18 | 2026-03-26 | 映恩生物科技(上海)有限公司 | 新型双特异性多肽复合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558811A1 (en) * | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
| JP6475167B2 (ja) * | 2012-12-21 | 2019-02-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質 |
| SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| WO2017151940A2 (en) * | 2016-03-03 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN111094333A (zh) * | 2017-06-01 | 2020-05-01 | 斯图加特大学 | 异源二聚化的Ig结构域 |
| AU2018290272A1 (en) * | 2017-06-21 | 2020-01-30 | Gsbio, Llc | Heterodimeric bispecific antibodies |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CN117843810A (zh) * | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| WO2019179627A1 (en) * | 2018-03-22 | 2019-09-26 | Universität Stuttgart | Multivalent binding molecules |
| KR20200142525A (ko) | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| CN112384243A (zh) * | 2018-04-17 | 2021-02-19 | 英温拉公司 | 三价三特异性抗体构建体 |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ, インコーポレイテッド | 多量体t細胞調節性ポリペプチド及びその使用方法 |
-
2022
- 2022-01-27 AU AU2022215712A patent/AU2022215712A1/en active Pending
- 2022-01-27 WO PCT/CN2022/074133 patent/WO2022166728A1/zh not_active Ceased
- 2022-01-27 CA CA3210307A patent/CA3210307A1/en active Pending
- 2022-01-27 BR BR112023015217A patent/BR112023015217A2/pt unknown
- 2022-01-27 TW TW111103599A patent/TW202233694A/zh unknown
- 2022-01-27 CN CN202280012964.0A patent/CN116964084A/zh active Pending
- 2022-01-27 JP JP2023545974A patent/JP2024507693A/ja active Pending
- 2022-01-27 MX MX2023008966A patent/MX2023008966A/es unknown
- 2022-01-27 KR KR1020237029391A patent/KR20230141817A/ko active Pending
- 2022-01-27 US US18/275,142 patent/US20240092899A1/en active Pending
- 2022-01-27 EP EP22749007.5A patent/EP4303231A4/en active Pending
- 2022-01-27 CN CN202410201902.5A patent/CN118063620A/zh active Pending
-
2023
- 2023-07-27 IL IL304800A patent/IL304800A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114885609A (zh) * | 2018-12-24 | 2022-08-09 | 赛诺菲 | 基于假Fab的多特异性结合蛋白 |
| CN114885609B (zh) * | 2018-12-24 | 2026-02-17 | 赛诺菲 | 基于假Fab的多特异性结合蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023015217A2 (pt) | 2023-11-07 |
| KR20230141817A (ko) | 2023-10-10 |
| EP4303231A4 (en) | 2025-02-26 |
| AU2022215712A1 (en) | 2023-09-07 |
| IL304800A (en) | 2023-09-01 |
| TW202233694A (zh) | 2022-09-01 |
| EP4303231A1 (en) | 2024-01-10 |
| MX2023008966A (es) | 2023-09-29 |
| CN118063620A (zh) | 2024-05-24 |
| WO2022166728A1 (zh) | 2022-08-11 |
| JP2024507693A (ja) | 2024-02-21 |
| US20240092899A1 (en) | 2024-03-21 |
| CA3210307A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7140861B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP6904902B2 (ja) | ドメイン交換抗体 | |
| JP6328087B2 (ja) | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 | |
| US20240092899A1 (en) | Bispecific antibody | |
| JP2021121642A (ja) | 二特異性抗体基幹 | |
| JP7600327B2 (ja) | Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途 | |
| JP2024507693A5 (cg-RX-API-DMAC7.html) | ||
| JP7123063B2 (ja) | 抗体ドメインの好ましい対形成 | |
| TWI918721B (zh) | Egfr結合複合物及其製備和使用方法 | |
| CN116888149A (zh) | 含异二聚体抗体Fc的蛋白以及其制备方法 | |
| WO2023038548A1 (ru) | Биспецифическое антитело, содержащее гетеродимер на основе мнс белков | |
| EA051713B1 (ru) | Биспецифическое антитело | |
| WO2025250941A1 (en) | Cμ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES | |
| CN121100128A (zh) | 异源多聚体多肽 | |
| EA041608B1 (ru) | Гетеродимерный полиспецифичный формат антител |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40097035 Country of ref document: HK |